Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3034% above fair value
$36.48+0.02 (+0.05%)
Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Pacira BioSciences's revenue for the twelve months ending Jun 30, 2026 was $746.16M, up 5.7% year over year. For fiscal 2025 it was $726.41M, up 3.6% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $726.41M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $726.41M | +3.6% |
| FY2024 | Dec 31, 2024 | $700.97M | +3.9% |
| FY2023 | Dec 31, 2023 | $674.98M | +1.2% |
| FY2022 | Dec 31, 2022 | $666.82M | +23.1% |
| FY2021 | Dec 31, 2021 | $541.53M | +26.0% |
| FY2020 | Dec 31, 2020 | $429.65M | +2.0% |
| FY2019 | Dec 31, 2019 | $421.03M | +24.8% |
| FY2018 | Dec 31, 2018 | $337.28M | +17.7% |
| FY2017 | Dec 31, 2017 | $286.63M | +3.7% |
| FY2016 | Dec 31, 2016 | $276.37M | +11.0% |
| FY2015 | Dec 31, 2015 | $249.00M | +26.0% |
| FY2014 | Dec 31, 2014 | $197.67M | +131.1% |
| FY2013 | Dec 31, 2013 | $85.55M | +118.9% |
| FY2012 | Dec 31, 2012 | $39.08M | +149.1% |
| FY2011 | Dec 31, 2011 | $15.69M | +7.7% |
| FY2010 | Dec 31, 2010 | $14.56M | -3.0% |
| FY2009 | Dec 31, 2009 | $15.01M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $192.40M | +6.2% |
| Q1 FY2026 | Mar 31, 2026 | $177.38M | +5.0% |
| Q4 FY2025 | Dec 31, 2025 | $196.87M | +5.1% |
| Q3 FY2025 | Sep 30, 2025 | $179.52M | +6.5% |
| Q2 FY2025 | Jun 30, 2025 | $181.10M | +1.7% |
| Q1 FY2025 | Mar 31, 2025 | $168.92M | +1.1% |
| Q4 FY2024 | Dec 31, 2024 | $187.25M | +3.3% |
| Q3 FY2024 | Sep 30, 2024 | $168.57M | +2.8% |
| Q2 FY2024 | Jun 30, 2024 | $178.02M | +5.0% |
| Q1 FY2024 | Mar 31, 2024 | $167.12M | +4.2% |
| Q4 FY2023 | Dec 31, 2023 | $181.24M | +5.4% |
| Q3 FY2023 | Sep 30, 2023 | $163.93M | -2.1% |
| Q2 FY2023 | Jun 30, 2023 | $169.47M | +0.0% |
| Q1 FY2023 | Mar 31, 2023 | $160.34M | +1.5% |
| Q4 FY2022 | Dec 31, 2022 | $171.96M | +8.0% |
| Q3 FY2022 | Sep 30, 2022 | $167.47M | +31.1% |
| Q2 FY2022 | Jun 30, 2022 | $169.41M | +24.9% |
| Q1 FY2022 | Mar 31, 2022 | $157.99M | +32.7% |
| Q4 FY2021 | Dec 31, 2021 | $159.19M | +21.5% |
| Q3 FY2021 | Sep 30, 2021 | $127.72M | +8.7% |
| Q2 FY2021 | Jun 30, 2021 | $135.59M | +79.6% |
| Q1 FY2021 | Mar 31, 2021 | $119.03M | +12.6% |
| Q4 FY2020 | Dec 31, 2020 | $130.97M | +7.0% |
| Q3 FY2020 | Sep 30, 2020 | $117.48M | +12.2% |
| Q2 FY2020 | Jun 30, 2020 | $75.51M | -26.4% |
| Q1 FY2020 | Mar 31, 2020 | $105.68M | +15.7% |
| Q4 FY2019 | Dec 31, 2019 | $122.42M | +28.7% |
| Q3 FY2019 | Sep 30, 2019 | $104.69M | +25.4% |
| Q2 FY2019 | Jun 30, 2019 | $102.60M | +22.0% |
| Q1 FY2019 | Mar 31, 2019 | $91.31M | +22.4% |
| Q4 FY2018 | Dec 31, 2018 | $95.12M | +20.3% |
| Q3 FY2018 | Sep 30, 2018 | $83.45M | +23.9% |
| Q2 FY2018 | Jun 30, 2018 | $84.11M | +18.6% |
| Q1 FY2018 | Mar 31, 2018 | $74.61M | +7.7% |
| Q4 FY2017 | Dec 31, 2017 | $79.08M | +8.5% |
| Q3 FY2017 | Sep 30, 2017 | $67.34M | -1.5% |
| Q2 FY2017 | Jun 30, 2017 | $70.93M | – |
| Q1 FY2017 | Mar 31, 2017 | $69.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $72.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $68.36M | – |
See a number that looks wrong?